Dr. B began as a virtual service providing access to Covid-19 vaccines and later Covid-19 treatments. It has now expanded to treatments for dermatology, sexual health, reproductive health and primary care.
Research conducted by the MIT Media Lab and Scale AI found that lighter skin tones vastly outnumber darker skin tones in the two of the most widely used dermatology atlases. This led to disparities in an AI model’s ability to diagnose skin conditions involving darker skin tones.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Direct-to-consumer health startup Hims bought dermatology business Apostrophe. It’s part of a broader push by the company to expand into more indications.
Google is making its first foray into patient-facing healthcare tools with a dermatology symptom-checker. Users take an image of the spot they’re concerned about and receive three potential “matches” for likely results.
In dermatology, to ensure that bias is not embedded in the technology, the machine learning algorithms must be trained using images of skin of color, not just light skin images.
Instead of suggesting a diagnosis for moles and skin lesions, digital health startup Miiskin is leaving that up to dermatologists. The company is rolling out a version of its tool for clinicians to make it easier for their patients to track moles and other spots on their skin.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
VisualDx got a grant for $655,535 from the Bill and Melinda Gates Foundation to build a tool that can allow health workers to diagnose skin conditions without a signal. The app uses images and a series of questions to point users toward a diagnosis.
The California-based dermatology company's lead product candidate is a Phase III monoclonal antibody being developed for a type of eczema. Another company, Denmark-based LEO Pharma, has a Phase III drug in the same class for the same disease.
The company is developing abrocitinib, a JAK1 inhibitor, for the disease. Incyte is also developing a topical formulation of its JAK2 inhibitor for atopic dermatitis.
Financial terms are undisclosed, but CEO says acquisition is second largest after 2016 Astellas dermatology purchase.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Physicians take an image with their iPhone or iPad of a skin discoloration and automatically receive three possible diagnoses classified as a weak match, good match, and best match.
A consumer-facing mobile and Web app allows patients to take photos of skin conditions and send the images to their physicians securely. It's not live, but rather store-and-forward technology.
Also, Biogen and University of Pennsylvania embark on gene therapy alliance and Mark Cuban said he was asked to run for president (and said no).
LEO Pharma, which has had a primary focus on skin conditions like psoriasis, has launched its new Innovation Lab to further explore treatment options that don't involve medication.
Wearable devices are not just for tracking fitness and overall health. Some are providing much more specific information and recommendations.